Cigna Under Investigation for Securities Violations by Schall Law Firm
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 day ago0mins
- Investigation Launched: The Schall Law Firm is investigating Cigna for potential violations of securities laws, focusing on whether the company issued false or misleading statements, indicating significant legal risks that could impact stock price and market trust.
- Investor Rights Protection: The firm encourages shareholders who suffered losses to participate in the investigation, highlighting a commitment to investor rights that may prompt increased shareholder attention and potential lawsuits, intensifying legal pressure on the company.
- Legal Expertise: Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, showcasing its expertise in this area, which may attract more investors seeking legal support and increase Cigna's legal burdens.
- Potential Consequences: Should the investigation confirm wrongdoing by Cigna, the company could face fines and reputational damage, which would adversely affect its long-term financial performance and market position.
CI.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 270.320
Low
294.00
Averages
337.60
High
378.00
Current: 270.320
Low
294.00
Averages
337.60
High
378.00
Guggenheim
Buy
maintain
$309 -> $318
2025-12-02
New
Reason
Guggenheim
Price Target
$309 -> $318
2025-12-02
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Cigna to $318 from $309 and keeps a Buy rating on the shares.
BofA
initiated
2025-11-19
Reason
BofA
Price Target
2025-11-19
initiated
Reason
BofA analysts added Cigna to the firm's "US 1 List," which represents a collection of its best investment ideas.
Bernstein
Lance Wilkes
Market Perform
downgrade
$346 -> $294
2025-11-12
Reason
Bernstein
Lance Wilkes
Price Target
$346 -> $294
2025-11-12
downgrade
Market Perform
Reason
Bernstein analyst Lance Wilkes lowered the firm's price target on Cigna to $294 from $346 and keeps a Market Perform rating on the shares following quarterly results. The firm is also adjusting its EPS model to reflect pressure in the PBM margin, with 2026 Evernorth earnings expected down 4% due to Pharmacy Benefit Services subsegment margin declining by an estimated 17%, offset by growth in the specialty segment and Cigna Healthcare.
Goldman Sachs
Scott Fidel
Buy
downgrade
$370 -> $330
2025-11-05
Reason
Goldman Sachs
Scott Fidel
Price Target
$370 -> $330
2025-11-05
downgrade
Buy
Reason
Goldman Sachs analyst Scott Fidel lowered the firm's price target on Cigna to $330 from $370 and keeps a Buy rating on the shares.
See All Ratings
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why does Trump oppose extending subsidies for the Affordable Care Act?
What are the key concerns of Republican lawmakers regarding ACA reform?
How might Trump's alternative healthcare proposal impact individual insurance buyers?
What could be the political consequences of the ACA subsidy debate?